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Abstract
Recent work suggests that herpes simplex virus (HSV) stromal keratitis in the mouse is caused by autoreactive T lymphocytes triggered
by a 16 amino acid region of the HSV UL6 protein (aa299–314) (Z.-S. Zhao, F. Granucci, L. Yeh, P. Schaffer, H. Cantor, 1998, Science
279, 1344–1347). In the present study we sought to determine whether genetic variation of this presumed autoreactive UL6 epitope is
responsible for different pathogenic patterns of human HSV keratitis. To accomplish this, we sequenced the HSV UL6 gene from ocular
isolates of 10 patients with necrotizing stromal keratitis, 7 patients with recurrent epithelial keratitis, and 8 patients with other forms of HSV
keratitis. The sequences obtained predicted identical UL6(299–314) epitopes for all 25 viral isolates. Furthermore, the upstream sequence
of all isolates was free of insertions, deletions, and stop codons. We conclude that different pathogenic patterns of human HSV keratitis
occur independent of genetic variation of the HSV UL6 (299–314) epitope.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Herpes simplex virus (HSV) stromal keratitis is the lead-
ing cause of infectious corneal blindness in developed coun-
tries. It is typically characterized by recurrent episodes of
inflammation resulting in scarring, thinning, and vascular-
ization of the corneal stroma. However, the spectrum of
corneal disease caused by HSV is extremely broad and
some patients never develop stromal disease despite multi-
ple recurrences of HSV infection of the corneal epithelium
(HEK). While most cases of the epithelial form of ocular
disease are effectively treated with a short course of a
topical or systemic antiviral, topical corticosteroids are the
mainstay of therapy for HSV stromal keratitis (HSK). The
immunopathological basis of HSK is highlighted by the
persistence of neutrophils, lymphocytes, cytokines, and che-
mokines in diseased corneas long after the clearance of
productive viral infection (Streilein et al., 1997).
Mouse models have been studied extensively to investigate
the immunopathogenesis of HSK (Thomas and Rouse, 1997),
and in one model mice developed autoreactive CD4 T cells
specific for an epitope in immunoglobulin G2ab (IgG2ab)
(Avery et al., 1995). Analysis of the HSV genome revealed a
close homology between the IgG2ab epitope and a 16 amino
acid region of the HSV UL6 protein [UL6(299–314)] (Zhao et
al., 1998), a component of the viral capsid (Patel and Maclean,
1995). In follow-up studies CD4 T cells from mice with HSV
stromal keratitis were found to be activated by a synthetic 16
amino acid peptide based on UL6(299–314), and mice in-
fected with a replication-defective UL6 deletion mutant failed
to develop the corneal inflammation and scarring characteristic
of this model (Zhao et al., 1998). Additional studies revealed
that a replication-competent viral mutant, engineered with a
single amino acid exchange at codon 309 of the HSV UL6
gene, was much less efficient at inducing HSK than wild-type
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virus (Panoutsakopoulou et al., 2001). The authors of these
studies conclude that murine HSK is caused by autoreactive T
cells triggered by a small region of the HSV UL6 protein.
However, recent work by Rouse and colleagues raises serious
questions about the role of molecular mimicry in the patho-
genesis of murine HSK and instead provides strong data to
support the hypothesis that the immunopathogenesis of HSK is
caused primarily by bystander activation of CD4 T cells (Desh-
pande et al., 2001; Gangappa et al., 1999).
It is tempting to speculate that an immunopathological
process, similar to that observed in the mouse, is responsible
for HSK in humans. If so, then the wide variation in clinical
presentation of HSV keratitis may be due, in part, to genetic
variation of the autoreactive UL6(299–314) epitope. The
goal of the current study was to determine whether differ-
ences in the predicted amino acid sequence of the HSV
UL6(299–314) correlate with the presence or absence of
stromal disease among patients with recurrent HSV kerati-
tis.
Results
Sequence of UL6 coding region in ocular viral isolates
We amplified and sequenced a fragment of the UL6 gene
(Fig. 1, Fragment A) from HSV-1 isolates of 10 patients
with HSK, 7 patients with a history of five or more episodes
of HEK (but no stromal thinning or vascularization), and 8
patients with HSV keratitis whose clinical history did not
fall into either of the above categories. The sequences ob-
tained predicted identical UL6(299–314) epitopes (nucleo-
tide positions 16,027 to 16,074) for all 25 ocular viral
isolates as well as for five viral laboratory strains (KOS,
ANG, HFEM, McIntyre, and McKrae). Some HSV isolates
contained variations at nucleotide positions 15,938 (C 3
T), 15,951 (C3 A), and 16,083 (T3 C), but these did not
change the predicted amino acid sequence of the UL6 pro-
tein.
We next amplified and directly sequenced nucleotides
15,132–15,933 (Fig. 1, Fragments B and C) from all ocular
isolates to investigate the possibility that mutations in the
upstream portion of the UL6 gene abolish expression of the
predicted UL6(299–314) epitope. Sequence comparison of
these isolates revealed no evidence of insertions, deletions,
or missense mutations that would disrupt the predicted
amino acid sequence of the UL6 protein. While several
nucleotide variations that alter the predicted UL6 amino
acid sequence were found, none were associated with a
specific pattern of clinical disease (Table 1).
UL6 RNA expression in infected A549 cells
Since it is possible that defects in the UL6 promoter
could abrogate transcription of UL6 RNA and thus prohibit
expression of the UL6(299–314) epitope, we next examined
expression of UL6 RNA in A549 cells infected with HSV
isolates from two eyes with HSK (samples 2 and 3) and eyes
with recurrent HEK but no stromal thinning or vasculariza-
tion (samples 11 and 12). As assayed by semiquantitative
RT-PCR, UL6 RNA was present in A549 cells infected with
HSV from both groups of patients (Fig. 2). A band of
similar size and abundance was observed following infec-
tion of cells with the HSV lab strain KOS. These results
demonstrate that the UL6 promoter was functional in HSV
isolates from both patients with HSK and those with recur-
rent HEK.
Discussion
HSV infection of the eye can lead to a wide spectrum of
HSV keratitis ranging from HEK to HSK. The reason for
Fig. 1. Schematic representation of the HSV genome showing the position of PCR primers (arrows) and amplified fragments for DNA sequencing (bars).
Nucleotide positions of the UL6 coding region are according to McGeoch (1988). The shaded region of the UL6 coding region represents nucleotides
16,027–16,074 and shows the approximate position of the UL6(299–314) peptide. Sequencing fragments A, B, and C represent amplification of nucleotides
15,912–16,190, 15,264–16,001, and 15,057–15,747, respectively. TRL, long terminal repeat; IRL, long internal repeat; IRS, short internal repeat; TRS, short
terminal repeat.
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this is not known. The recent finding that HSK in the mouse
is caused by autoreactive T cells triggered by the HSV
UL6(299–314) epitope (Zhao et al., 1998; Panoutsakopou-
lou et al. 2001) prompted us to study banked HSV1 isolates
from patients with HSK and those with recurrent epithelial
keratitis but no evidence of stromal necrosis to determine
whether variations in the DNA sequence encoding the
UL6(299–314) epitope might account for the variable clin-
ical presentation of recurrent HSV keratitis. Analysis of the
UL6 gene sequence of ocular viral isolates from 25 patients
with varying patterns of recurrent HSV keratitis revealed no
polymorphisms that would predict altered expression of the
UL6(299–314) epitope. Thus, polymorphisms in the HSV
UL6 gene are not responsible for the variable presentation
of keratitis in patients with recurrent ocular HSV infection.
It is important to point out that our data do not com-
pletely rule out a role for the HSV UL6 gene product in the
pathogenesis of human HSK. Just as different strains of
mice develop either necrotizing or nonnecrotizing keratitis
as a consequence of genetic differences in their immune
responsiveness to the UL6(299–314) epitope (Zhao et al.,
1998), the variable clinical presentation of HSV keratitis in
humans may be a consequence of heterogeneity in the
immune response. Alternatively, the broad spectrum of
HSV keratitis in humans may be a consequence of hetero-
geneity in host expression of putative corneal autoantigens.
Thus, it is still possible that the UL6 protein triggers HSV
necrotizing keratitis in humans, but only in genetically pre-
disposed individuals.
In light of the above discussion, demonstration of a role
for the UL6 gene product in the pathogenesis of HSK in
humans will likely depend upon clinical studies that dem-
onstrate the presence of corneal lymphocytes in patients
with HSK that are reactive to both the HSV UL6 protein and
the corneal antigens. Although investigators have success-
fully isolated HSV-specific CD4 T cells from a small
number of human corneas with HSK, these T lymphocytes
did not appear to react to either the HSV UL6 protein or the
corneal antigens (Verjans et al., 1998, 2000; Koelle et al.,
2000). Taken together with our data, this suggests that,
unlike the mouse, HSK in humans is not an autoreactive
process triggered by a 16 amino acid region of the HSV
UL6 protein.
Table 1
Predicted UL6 amino acid (aa) sequence variations of HSV isolates as compared to HSV strain 17a
aa 33b aa 92c aa 96d aa 154e aa 155f
Lab strains
KOS Ser 3 Thr wt wt wt wt
ANG ND Gly 3 Cys wt Pro 3 Leu Ser 3 Thr
McKrae, McIntyre, HFEMg ND wt wt wt wt
HSK isolates
1, 3 Ser 3 Thr wt wt wt wt
2 Ser 3 Thr Gly 3 Cys Ala 3 Val Pro 3 Leu Ser 3 Thr
4, 5, 6, 8 wt wt wt wt wt
7, 9, 10 wt Gly 3 Cys wt Pro 3 Leu Ser 3 Thr
HEK isolates
15, 16, 17 wt wt wt wt wt
11, 12, 13, 14 Ser 3 Thr Gly 3 Cys wt Pro 3 Leu Ser 3 Thr
Other isolates
18, 19, 20, 21, 22, 25 wt wt wt wt wt
23, 24 wt Gly 3 Cys wt Pro 3 Leu Ser 3 Thr
Note. wt, wild-type; ND, not determined; HSK, HSV stromal keratitis; HEK, recurrent HSV epithelial keratitis.
a Nucleotide and amino acid positions are according to McGeoch et al. (1988).
b G15,176 3 C.
c G15,405 3 T.
d G15,418 3 C.
e G15,592 3 T.
f G15,594 3 A and A15,596 3 C.
g HFEM contains the additional variation of Ala 3 Thr (G15,369 3 A) at aa position 80.
Fig. 2. Analysis of HSV UL6 RNA by RT-PCR. RNA from HSV-infected
A549 cells was subjected to RT-PCR analysis as described under Materials
and methods. RT-PCR of G3PDH RNA from each set of infected and
uninfected cells served as loading control. Reactions were performed with
() and without () reverse transcriptase to verify RNA samples did not
contain contaminating DNA. Lanes are as follows: HSV lab strain KOS
(lanes 1,  and ), HSV isolate 11 (lanes 2,  and ), HSV isolate 12
(lanes 3,  and ), HSV isolate 3 (lanes 4,  and ), HSV isolate 2 (lanes
5,  and ), and uninfected cells (lanes 6,  and ). HSV ocular isolates
2 and 3 were from patients with herpes simplex stromal keratitis. HSV
ocular isolates 11 and 12 were from patients with recurrent herpes simplex
epithelial keratitis but no stromal thinning or vascularization.
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Materials and methods
Laboratory HSV-1 strains
HSV type 1 strain KOS has been propagated in our
laboratory for many years. Strains ANG and McKrae were
gifts of D. Bloom (University of Florida). Strain HFEM was
a gift of B. Mitchell (Baylor School of Medicine). Strain
McIntyre was purchased from Advanced Biotechnologies
Inc. (Columbia, MD).
Patient diagnosis, HSV specimen collection, and
preparation of viral DNA
Banked clinical HSV isolates were obtained from the
clinical microbiology lab at the F. I. Proctor Foundation
(University of California at San Francisco) and the Camp-
bell Microbiology Laboratory at the University of Pitts-
burgh Ear and Eye Institute. The definition of HSK varies
widely between institutions and among experts in the field.
For the purposes of this study, we defined HSK as a keratitis
with decreased corneal sensation, thinning, or vasculariza-
tion of the cornea stroma, and history of a positive ocular
viral culture for HSV-1. This study was approved by the
UCSF Committee on Human Research and adheres to the
Declaration of Helsinki for research involving human sub-
jects.
Viral cultures of corneal scrapings were performed on
human bronchial carcinoma (A549) cells (Bartels Inc., Is-
saquah, WA). All viral isolates were passaged less than two
times. Infected cells were lysed at 37°C in a solution con-
taining 10 mM Tris–HCl (pH 8.0), 300 mM sodium acetate,
1 mM EDTA, 0.5% sodium dodecyl sulfate (SDS), and 0.2
mg/ml proteinase K (Sigma Chemical Co., St. Louis, MO).
Cell lysates were frozen at20°C and centrifuged at 12,000
g for 15 min at 4°C to remove SDS–protein complexes. The
supernatant fluid containing viral DNA was stored at
20°C.
PCR amplification and sequence analysis of the UL6 gene
The UL6 gene is located between nucleotides 15,132 and
17,160 of the HSV1 genome (McGeoch et al., 1988). Re-
gions of the UL6 gene were amplified by PCR prior to direct
sequencing. To accomplish this viral isolates (10–20 l)
were brought to a final volume of 100 l in a mixture
containing 20 mM Tris–HCl (pH 8.8), 10 mM KCl, 10 mM
(NH4)2SO4, 2.5 mM MgSO4, 0.2 mM of each dNTP, 0.1
M of sense and antisense oligonucleotide primers, 10%
DMSO, 0.1% Triton X-100, 100 g/ml bovine serum albu-
min and 50 U/ml PFU DNA polymerase (Stratagene, La
Jolla, CA). The primers used were UL6-1 (5-TTG TGG
ACC GGG GAC CGT CTG-3), UL6-2 (5-GTG GCG
CAT GCC CTT CAT GTT G-3), UL6-8 (5-GGG CAG
CTG GGG TAT ACC GAG-3), UL6-11 (5-CGC GTG
TTC CCG GAG GGA GTG-3), UL6-10 (5-CCG CGG
CCT CCG CGA CCG TG-3), and UL6-12 (5- GTC CCC
GGG TTG CTG AAG GTG-3). Thermocycling conditions
were as follows: 94°C for 2 min followed by 37 cycles of
94°C for 36 s, 55°C for 2 min, and 72°C for 2.5 min. To
validate successful amplification by PCR, an aliquot of the
PCR product was electrophoresed on a 2% agarose gel
containing 0.25 g/ml ethidium bromide. The remaining
sample was purified with Centricon-40 columns (Princeton
Separations, Adelphia, NJ) for direct sequencing using the
ABI Prism Dye Terminator Cycle Sequencing Kit (Perkin–
Elmer, Foster City, CA).
RNA preparation from infected cells
A549 cells were infected with HSV and grown at 37°C
until 100% of the monolayer exhibited cytopathic effect. At
this stage, growth media was removed; cells were washed
with phosphate-buffered saline (pH 7.4), and total RNA was
prepared using TRIzol reagent (Life Technologies, Gaith-
ersburg, MD). RNA samples were treated with a solution
containing 0.8 U/ml RNase-free DNase I (Roche Molecular
Biochemicals, Indianapolis, IN), 10 mM MgCl2, 0.1 mM
dithiothreitol, and 0.7 U/ml RNase Inhibitor (Roche Molec-
ular Biochemicals) at 37°C for 60 min. RNA was then
purified by phenol–chloroform extraction, precipitated with
ethanol, and resuspended in diethyl pyrocarbonate-treated
H2O.
Reverse transcription (RT)-PCR
RNA (1.5 g) was reverse transcribed in a 20-l mixture
containing 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 0.5 mM of each dNTP, 2 U/l RNase
Inhibitor (Roche Molecular Biochemicals), 2.5 M random
hexamer (Pharmacia, Piscataway, NJ), and 10 U/l Molo-
ney murine leukemia virus (M-MLV) reverse transcriptase
(Gibco-BRL, Grand Island, NY). Samples were incubated
at 23°C for 10 min, 37°C for 45 min, 95°C for 5 min, and
18°C for 1 min. An aliquot representing 1/25th of the
resultant first-strand cDNA was amplified by PCR as de-
scribed above. For the HSV-1 UL6 gene, primers UL6-1
and UL6-2 were used. For the cellular glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) gene, primers
G3PDH-1 (5-ACC ACA GTC CAT GCC ATC AC-3) and
G3PDH-2 (5-TCC ACC ACC CTG TTG CTG TA-3)
were used.
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